Dr. Mike Tranfaglia explains how FRAXA prioritizes Fragile X research and the importance of looking at research from multiple angles. "It's not either-or. It's not we have a definitive treatment or we have a new drug treatment or we have a repurposing treatment. We can have all of those things, mixed or matched, in a personalized medicine kind of way and I think that's what we're headed for."